Strategic partnership HaploX's collaboration with Illumina to co-develop a domestically produced flagship benchtop sequencing system presents a clear entry point for sales partnerships, co-marketing opportunities, and integration with Illumina-enabled workflows.

AI and data The company combines liquid biopsy, gene sequencing, AI, and big data analytics, signaling strong potential for selling advanced bioinformatics software, cloud analysis services, and data management solutions to cancer centers and large labs seeking end-to-end genomic analysis.

Global footprint With a polycentric presence including R&D in Shenzhen and the US, a GMP factory, and international health industrial park collaborations, HaploX is positioned to scale through regional distributors, international labs, and cross-border sales initiatives.

Quality and credibility EMQN participation and external quality assessments in NSCLC and oncogene panels emphasize reliability; this can be leveraged to target hospitals and clinics prioritizing validated liquid biopsy assays and accreditation-aligned vendors.

Growth and funding Recent funding and a growing revenue range indicate expanding capacity and demand; sales efforts can focus on mid-market oncology centers and contract research organizations seeking scalable sequencing solutions and integrated platforms.